Xylometazoline with ipratropium nasal
- Drugs List
- Therapeutic Indications
- Dosage
- Administration
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Nasal spray containing xylometazoline hydrochloride and ipratropium bromide.
Drugs List
Therapeutic Indications
Uses
Nasal congestion (topical treatment)
Symptomatic treatment of nasal congestion and rhinorrhea associated with common colds.
Dosage
Adults
1 spray into each nostril up to three times a day with at least 6 hours between doses. The total daily administration should not exceed 3 sprays into each nostril.
Treatment should not exceed seven days.
Once control of symptoms has been established, it is recommended to cease treatment even before maximum duration of seven days.
Administration
Actuate pump 4 times before first application. During use, if spray does not eject or if medication has not been used for longer than six days, reprime with 4 actuations.
Contraindications
Children under 18 years
Glaucoma
Recent nasal surgery
Precautions and Warnings
Elderly
Predisposition to narrow angle glaucoma
Predisposition to paralytic ileus
Recurrent epistaxis
Benign prostatic hyperplasia
Bladder outflow obstruction
Breastfeeding
Cardiovascular disorder
Cystic fibrosis
Diabetes mellitus
Hypertension
Hyperthyroidism
Long QT syndrome
Phaeochromocytoma
Pregnancy
Not suitable for use in rhinitis sicca
Advise ability to drive/operate machinery may be affected by side effects
Avoid spray in or near eyes
If accidental contact with the eyes occurs, rinse thoroughly with water
Treatment should be for a maximum period of 7 days
Advise patient to consult a doctor if symptoms persist despite treatment
Pregnancy and Lactation
Pregnancy
Use xylomatazoline and ipratropium bromide nasal spray with caution during pregnancy.
The manufacturer recommends this medication is not used during pregnancy unless the potential benefit to the mother outweighs the potential risk to the foetus. Animal studies are inadequate regarding effects on pregnancy, embryonal/foetal development, parturition and postnatal development. At the time of writing there is limited human data available. Risks are unknown.
Lactation
Use xylomatazoline and ipratropium bromide nasal spray with caution during breastfeeding.
The manufacturer recommends this medication is not used during breastfeeding unless the potential benefit to the mother outweighs the potential risk to the infant. It is unknown if xylometazoline and ipratropium bromide are excreted into breast milk but systemic exposure is low and effects on the breastfed infant are unlikely.
Side Effects
Atrial fibrillation
Blurred vision
Chest discomfort
Cough
Disturbances in accommodation
Dizziness
Dry mouth
Dry throat
Dryness and irritation of eyes
Dysgeusia
Dyspepsia
Dysphagia
Dysphonia
Epistaxis
Fatigue
General discomfort
Headache
Hypersensitivity reactions
Increased intra-ocular pressure
Insomnia
Laryngospasm
Mydriasis
Narrow angle glaucoma
Nasal congestion
Nasal discomfort
Nasal dryness
Nasal ulceration
Nausea
Ocular pain
Oropharyngeal pain
Palpitations
Parosmia
Pharyngeal oedema
Photopsia
Pruritus
Rash
Rhinorrhoea
Sinus disorder
Sneezing
Sore nose
Tachycardia
Thirst
Throat irritation
Tremor
Urinary retention
Urticaria
Visual haloes
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: October 2019
Reference Sources
Summary of Product Characteristics: Otrivine Extra Dual Relief nasal spray, solution. GlaxoSmithKline Consumer Healthcare (UK) Trading Limited.
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.